Floatz logo

Carboplatin

Carcinoma of the Appendix

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Carcinoma of the Appendix cohort.

Asset / SponsorPhaseRating
MITOMYCIN C
City of Hope Medical Center
Phase 3BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Irinotecan
City of Hope Medical Center
Phase 3BB
Thalidomide
Wake Forest University Health Sciences
Phase 2B
Palonosetron
Alliance for Clinical Trials in Oncology
Phase 2CCC

View all 17 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →